Similar articles for PMID: 23243609

Year	Number of Results
1996	1
1997	1
1999	2
2000	1
2001	3
2002	2
2003	5
2004	4
2005	5
2006	6
2007	5
2008	2
2009	2
2010	3
2011	3
2012	6
2013	4
2014	1
2015	4
2016	3
2017	8
2018	3
2019	7
2020	9
2021	5
2024	0

1

High-throughput approaches to discover novel immunomodulatory agents for cancer.

McMillin DW, Mitsiades CS. McMillin DW, et al. Oncoimmunology. 2012 Nov 1;1(8):1406-1408. doi: 10.4161/onci.21058. Oncoimmunology. 2012. PMID: 23243609 Free PMC article.

2

Thalidomide: an old drug with new action.

Kumar V, Chhibber S. Kumar V, et al. J Chemother. 2011 Dec;23(6):326-34. doi: 10.1179/joc.2011.23.6.326. J Chemother. 2011. PMID: 22233815 Review.

3

Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents.

El-Zahabi MA, Sakr H, El-Adl K, Zayed M, Abdelraheem AS, Eissa SI, Elkady H, Eissa IH. El-Zahabi MA, et al. Bioorg Chem. 2020 Nov;104:104218. doi: 10.1016/j.bioorg.2020.104218. Epub 2020 Sep 1. Bioorg Chem. 2020. PMID: 32932121

4

Thalidomide and immunomodulatory drugs as cancer therapy.

Raje N, Anderson KC. Raje N, et al. Curr Opin Oncol. 2002 Nov;14(6):635-40. doi: 10.1097/00001622-200211000-00008. Curr Opin Oncol. 2002. PMID: 12409654 Review.

5

Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.

Bodera P, Stankiewicz W. Bodera P, et al. Recent Pat Endocr Metab Immune Drug Discov. 2011 Sep;5(3):192-6. doi: 10.2174/187221411797265890. Recent Pat Endocr Metab Immune Drug Discov. 2011. PMID: 21913886 Review.

6

Innate immune cells for immunotherapy of autoimmune and cancer disorders.

Schäfer C, Ascui G, Ribeiro CH, López M, Prados-Rosales R, González PA, Bueno SM, Riedel CA, Baena A, Kalergis AM, Carreño LJ. Schäfer C, et al. Int Rev Immunol. 2017 Nov 2;36(6):315-337. doi: 10.1080/08830185.2017.1365145. Epub 2017 Sep 21. Int Rev Immunol. 2017. PMID: 28933579 Review.

7

[The return of thalidomide].

Rossi G. Rossi G. Recenti Prog Med. 2001 Mar;92(3):213-6. Recenti Prog Med. 2001. PMID: 11320855 Review. Italian.

8

Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review).

Wang X, Shen Y, Li S, Lv M, Zhang X, Yang J, Wang F, Yang J. Wang X, et al. Int J Mol Med. 2016 Oct;38(4):1021-9. doi: 10.3892/ijmm.2016.2724. Epub 2016 Aug 31. Int J Mol Med. 2016. PMID: 27599781 Review.

9

Properties of thalidomide and its analogues: implications for anticancer therapy.

Teo SK. Teo SK. AAPS J. 2005 Mar 22;7(1):E14-9. doi: 10.1208/aapsj070103. AAPS J. 2005. PMID: 16146335 Free PMC article. Review.

10

Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.

Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H, Kubo T, Shimose S, Kimura A. Munemasa S, et al. Int J Oncol. 2008 Jul;33(1):129-36. Int J Oncol. 2008. PMID: 18575758

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

90 results

Results by year